ANDA 207667, held by Eugia Pharma. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 207667 (Methylprednisolone Sodium Succinate), held by Eugia Pharma, was first approved by FDA on Dec 15, 2015, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 15, 2015 | Original application | Approved | None posted |
| Methylprednisolone Sodium SuccinateEQ 40MG BASE/VIAL ยท injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Methylprednisolone Sodium SuccinateEQ 125MG BASE/VIAL ยท injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Methylprednisolone Sodium SuccinateEQ 500MG BASE/VIAL ยท injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Methylprednisolone Sodium SuccinateEQ 2GM BASE/VIAL ยท injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Nov 13, 2024 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Nov 13, 2024 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Apr 2, 2020 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Apr 2, 2020 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Dec 15, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters